ITRM Earnings

ITRM reported its FY2025Q3 earnings on 2025-11-14, showcasing a revenue of 390.00K against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.13 by 0% . The stock experienced a -16.11% price change on the earnings day and a -31.3% change over the next five days, reflecting market reactions to the results.

Following ITRM's FY2025Q3 earnings announcement on 2025-11-14, the stock price moved by -16.11% on the day of the release. Over the subsequent five days, it saw a -31.30% change. Historically, ITRM's stock price tends to shift by an average of +5.71% in the 10 days leading up to earnings and +14.91% in the 10 days following, providing insight into potential market.

For , analysts estimate ITRM’s annual revenue to reach , while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -9.6% and EPS estimates Revise Downward by -15.83% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between ITRM's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -9.6%, while EPS estimates moved Revise Downward by -15.83% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ITRM's stock price typically moves by +5.71% in the 10 days before its earnings and +14.91% in the 10 days after. For the upcoming earnings, analysts expect an EPS of 0.00 and revenue of .

The earnings call reveals a concerning financial performance with a widening net loss and increased expenses due to commercialization activities. The Q&A highlighted uncertainties about payer coverage and formulary approvals, which are crucial for future sales. While there is positive physician feedback, the limited current coverage and the lack of detailed guidance on key metrics contribute to a negative outlook. The stock is likely to react negatively in the short term due to these uncertainties and financial pressures.